UiPath (PATH) Q2 2027 Earnings Call Transcript

UiPath reported fiscal Q2 2027 revenue of $410 million, up 13% year over year, and ARR of $1.938 billion, up 12%, while net new ARR rose to $37 million from $31 million. Non-GAAP operating income reached $89 million, or a 22% margin, and GAAP operating income was $32 million versus a $20 million loss a year earlier, marking a fourth consecutive profitable quarter. AI was attached to 18 of the company’s 20 largest deals, cloud ARR grew 19% to $1.3 billion, and customers with more than $1 million in ARR increased 21% to 387. Full-year guidance calls for $1.789-$1.794 billion of revenue, $2.065-$2.070 billion of ARR, $445 million of non-GAAP operating income, and $425 million of adjusted free cash flow, despite a $20 million FX revenue headwind.

Analysis

PATH’s investable change is not the AI attachment statistic itself, but the emerging proof that AI is lifting contract size while its deterministic automation layer protects customers from open-ended inference costs. If transaction/outcome pricing is adopted, PATH can convert a historically seat/license-oriented business into a higher-ARPU consumption model; the offset is that gross-margin durability becomes dependent on model-cost pass-through and usage controls. The key near-term valuation question is whether the improving ARR trajectory can clear 110% NRR without additional sales-and-marketing investment, rather than whether margins can expand further through cost control.

The strongest second-order beneficiary is CTSH: embedding Test Cloud in managed testing gives Cognizant a differentiated delivery offering and potentially more implementation volume, while PATH gains distribution without carrying all services headcount. Conversely, ServiceNow (NOW), Microsoft (MSFT), Salesforce (CRM), and automation specialists such as Pegasystems (PEGA) have a clear incentive to bundle orchestration into broader enterprise contracts; PATH’s model-agnostic positioning is a buying advantage only while customers resist platform consolidation around their existing hyperscaler.

For days to 1-3 months, Investor Day/FUSION is the catalyst, but expectations should be constrained: management has not quantified AI ARR, realized implementation savings, pricing, or conversion from pilots to production. The 6-18 month upside rests on vertical solutions creating repeatable sales motions in financial services, healthcare revenue cycle, and CFO workflows. Thesis failure would be NRR remaining below 110%, net-new ARR reverting after the current quarter, cloud growth decelerating materially, or FY28 margin/FCF guidance revealing that implementation support and AI inference costs absorb the claimed productivity gains.

Contrarian view: the market may over-credit AI narrative before seeing monetization, but may under-credit the balance-sheet-supported buyback and operating leverage if enterprise consolidation actually reduces churn and partner-led delivery scales. PATH is not yet a clean AI infrastructure proxy; it is a turnaround software name whose multiple should rerate only on evidence of sustained expansion-led growth.

Key Decisions for Investors

• Maintain/establish a tactical long PATH only on post-event confirmation: add if Investor Day discloses AI/agentic ARR or usage KPIs and reiterates/improves ARR outlook. Target a 10-15% upside over 1-3 months on multiple expansion; exit if management cannot quantify monetization or Q3 net-new ARR falls below the prior-quarter run rate.
• Use a defined-risk structure rather than chase an earnings gap: buy 3-6 month PATH call spreads funded partly with out-of-the-money puts only after implied volatility is reviewed against the post-event range. The missing input is current option skew and implied move; without it, treat this as an execution alert, not a live recommendation.
• Pair long PATH / short PEGA over 6-12 months in equal beta-adjusted dollars if enterprise consolidation wins continue. PATH has greater upside to improving retention and AI-driven deal size; PEGA is exposed to similar workflow-automation spending but has less turnaround operating leverage. Cover if PATH NRR fails to exceed 109-110% by the next two reports.
• Add CTSH selectively ahead of evidence of Test Cloud implementation bookings, not merely partnership announcements. A measurable increase in digital-engineering bookings or margin-accretive managed-testing mix would validate a partner-channel spillover; absent disclosure, no standalone catalyst is established.